Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804048 | 1.00 | HPGD (0.62) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL10233234 | 1.00 | HPGD (0.62) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL3321211 | 0.90 | MEN1 (0.68) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL2728409 | 0.90 | MEN1 (0.68) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL3608462 | 0.90 | MEN1 (0.68) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL2015039 | 0.89 | HPGD (0.66) | HPGDKMT2AMAPTRECQLEPHX1 | |
| SCHEMBL21954154 | 0.89 | MEN1 (0.63) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL26828253 | 0.88 | HPGD (0.60) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL28263415 | 0.88 | HPGD (0.64) | HPGDKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL42958 | 0.86 | HPGD (0.62) | HPGDKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747256-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4680609-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-12421254-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-118147098-B | Leucine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis | 江南大学 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025049402-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250051365-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025026745-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-02-06 | — | — | WO | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HPGD 972/4885KMT2A 2160/4885MEN1 3756/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | HPGD 3307/4885KMT2A 4396/4885MEN1 2714/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | HPGD 4250/4885KMT2A 288/4885MEN1 1884/4885 |
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | HPGD 2973/4885KMT2A 3175/4885MEN1 646/4885 |
| US-12421254-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | HPGD 1514/4885KMT2A 3284/4885MEN1 449/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | HPGD 1489/4885KMT2A 3772/4885MEN1 2199/4885 |
| US-20250051365-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | HPGD 2502/4885KMT2A 3705/4885MEN1 458/4885 |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | HPGD 1081/4885KMT2A 841/4885MEN1 3540/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HPGD 410/4885KMT2A 977/4885MEN1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.